Proteomics: New Frontiers

Proteomics is the direct study of the proteins produced by genes and an alternative and complementary approach to genomic-based investigations. Proteomics aims to identify and validate the proteins that drive core biological functions, and describe changes in protein expression under the influence of disease or pharmacotherapy. High-throughput proteomic technologies are still in the early phases of development. Analogous to microarrays for functional gene expression analyses, such approaches have great potential to be used in developing new pharmacotherapies and other targeted therapies.

The majority of pharmaceuticals currently available are natural products created from biochemical discoveries in humans, animals, and plants. Proteomics provides the opportunity to develop targeted therapies based on human biology, which have significant advantages over traditional drugs. Key amongst these are heightened efficacy, reduced side effects, lower toxicity hazards, and markedly lower time and cost associated with commercialization.

Recombinant insulin, one of the first engineered protein therapies, was approved in 1982. Since that time, the pharmaceutical industry has devoted tremendous resources to develop engineered proteins for therapy. The recent completion of the first draft of the Human Genome Project, together with technical advances in the laboratory, will dramatically accelerate the development of new protein therapies. An example of a promising protein based therapy is the recent human trials of treatments for heart disease using proteins that encourage lateral growth of blood vessels in the heart, eliminating the need for bypass surgery. Another group of proteins in clinical trials are those that turn off the blood supply around cancer cells, called angiogenesis inhibitors. These proteins cause regression of tumors in mice and may be the method to eradicate some types of cancer.

The market for all drug therapies is currently $400 billion, and is expected to grow to a multi-trillion dollar market, of which a great proportion will be protein based therapies. Triaj offers a comprehensive range of services related to proteomics, ranging from general advisory and project review to large scale applied consulting projects. Triaj's biotechnology professionals are recognized international leaders in their fields, and include experts in genetics, genomics, proteomics, molecular biology, genetic statistics, clinical epidemiology, genetic epidemiology, biostatistics, bioinfomatics, diagnostics, therapeutics, and gene mapping. Triaj's professional staff has an unparalleled wealth of expertise in all aspects of proteomics, including study design, gene expression and microarray analysis, generation of molecular data, and biostatistical analysis.

Profit from Triaj's experience.

Triaj's professional staff collectively has over sixty published articles in peer reviewed scientific journals of direct relevance to proteomics, which represents approximately 20% of all articles published worldwide in this new science. Triaj's professional staff has also published over three thousand articles in the peer-reviewed scientific literature in the related fields of clinical epidemiology, clinical genetics, genetic epidemiology, statistical methodology, bioinformatics, pharmacogenomics, functional genomics and gene discovery. Our professional staff have extensive experience in the analysis of gene expression data and in consulting to industry in this area.

---

Back to Expertise